Orphenadrine induces secondarily generalized convulsive status epilepticus in rats

Brain Research Bulletin

Volumn 84, Issue 6, 2011, Pages 389-393

  Rejdak, Konrad ^a   Nieoczym, Dorota ^b   Czuczwar, Mirosław ^a   Kiś, Jacek ^a   Wlaź, Piotr ^b   Turski, Waldemar A ^a,c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^c INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Convulsive status epilepticus; New model; Orphenadrine; Rats

Indexed keywords

CARBAMAZEPINE; DIAZEPAM; ETHOSUXIMIDE; ORPHENADRINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BEHAVIORAL SCIENCE; CONTROLLED STUDY; DISEASE DURATION; DRUG POTENCY; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; HISTOPATHOLOGY; LATENT PERIOD; LETHALITY; LIMB MOVEMENT; MALE; MUSCLE TWITCH; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICONVULSANTS; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; HUMANS; MALE; ORPHENADRINE; RANDOM ALLOCATION; RATS; RATS, WISTAR; STATUS EPILEPTICUS;

EID: 79953049262     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2011.01.014     Document Type: Article

References (23)

1. Beyenburg S., Stavem K., Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 2010, 51:7-26.
2. Buckley N., McManus P. Fatal toxicity of drugs used in the treatment of psychotic illnesses. Br. J. Psychiatr. 1998, 172:461-464.
3. Bymaster F.P., Heath I., Hendrix J.C., Shannon H.E. Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J. Pharmacol. Exp. Ther. 1993, 267:16-24.
4. Czuczwar M., Cieszczyk J., Czuczwar K., Kis J., Saran T., Turski W.A. Influence of orphenadrine upon the protective activity of various antiepileptics in the maximal electroshock-induced convulsions in mice. Pharmacol. Rep. 2009, 61:732-736.
5. Desaphy J.F., Dipalma A., De Bellis M., Costanza T., Gaudioso C., Delmas P., George A.L., Camerino D.C. Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain 2009, 142:225-235.
6. Klitgaard H., Matagne A., Gobert J., Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 1998, 353:191-206.
7. Kornhuber J., Parsons C.G., Hartmann S., Retz W., Kamolz S., Thome J., Riederer P. Orphenadrine is an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J. Neural Transm. Gen. Sect. 1995, 102:237-246.
8. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-response experiments. J. Pharmacol. Exp. Ther. 1949, 96:99-113.
9. Millar W.M. Deaths after overdoses of orphenadrine. Lancet 1977, 2:566.
10. Navarro M.G., Bramanti P., Osculati F., Chakir A., Nicolato E., Marzola P., Sbarbati A., Fabene P.F. Does pilocarpine-induced epilepsy in adult rats require status epilepticus?. PLoS One 2009, 4:e5759.
11. Neligan A., Shorvon S.D. The history of status epilepticus and its treatment. Epilepsia 2009, 50(Suppl. 3):56-68.
12. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, Sydney. 4th edn.
13. Perucca E., French J., Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 2007, 6:793-804.
14. Pubill D, Verdaguer E., Canudas A.M., Sureda F.X., Escubedo E., Camarasa J., Pallas M., Camins A. Orphenadrine prevents 3-nitropropionic acid-induced neurotoxicity in vitro and in vivo. Br. J. Pharmacol. 2001, 132:693-702.
15. Roozemond R.C., Hespe W., Nauta W.T. The concentrations of orphenadrine and its N-demethylated derivatives in rat brain, after intraperitoneal administration of orphenadrine and tofenacine. Int. J. Neuropharmacol. 1968, 7:293-300.
16. Scholz E.P., Konrad F.M., Weiss D.L., Zitron E., Kiesecker C., Bloehs R., Kulzer M., Thomas D., Kathofer S., Bauer A., Maurer M.H., Seemann G., Katus H.A., Karle C.A. Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656. N. S. Arch. Pharmacol. 2007, 376:275-284.
17. Smith M., Wilcox K.S., White H.S. Discovery of antiepileptic drugs. Neurotherapeutics 2007, 4:12-17.
18. Stables J.P., Bertram E., Dudek F.E., Holmes G., Mathern G., Pitkanen A., White H.S. Therapy discovery for pharmacoresistant epilepsy and for disease-modifying therapeutics: summary of the NIH/NINDS/AES models II workshop. Epilepsia 2003, 44:1472-1478.
19. Sureda F.X., Gabriel C., Pallas M., Adan J., Martinez J.M., Escubedo E., Camarasa J., Camins A. In vitro and in vivo protective effect of orphenadrine on glutamate neurotoxicity. Neuropharmacology 1999, 38:671-677.
20. Turski W.A., Cavalheiro E.A., Schwarz M., Czuczwar S.J., Kleinrok Z., Turski L. Limbic seizures produced by pilocarpine in rats: behavioural, electroencephalographic and neuropathological study. Behav. Brain Res. 1983, 9:315-335.
21. Walton N.Y., Treiman D.M. Response of status epilepticus induced by lithium and pilocarpine to treatment with diazepam. Exp. Neurol. 1988, 101:267-275.
22. Walton N.Y., Treiman D.M. Phenobarbital treatment of status epilepticus in a rodent model. Epilepsy Res. 1989, 4:216-221.
23. Walton N.Y., Treiman D.M. Valproic acid treatment of experimental status epilepticus. Epilepsy Res. 1992, 12:199-205.